Benzinga | Jul 15, 2020 08:33AM EDT

Evofem Biosciences Highlights Peer-Reviewed Publication Of Pivotal Phase 3 AMPOWER Study Results For Phexxi (lactic acid, citric acid and potassium bitartrate) In Contraception

SAN DIEGO, July 15, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a commercial-stage biopharmaceutical company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary efficacy and safety results from the Phase 3 AMPOWER study evaluating Phexxi(tm) (lactic acid, citric acid and potassium bitartrate) for the prevention of pregnancy. The results were published "online first" this week in Contraception: X ( https://bit.ly/38HLFBh) and will appear in a future print edition of the journal.